Influenza Virus Vaccine
drugOn this page
Also known as Influenzalive attenuated
Summary
Influenza Virus Vaccine (CHEMBL2109042) is a phase-3 clinical-stage vaccine component (ATC J07BB03); indicated across 33 conditions including relapsing-remitting multiple sclerosis and herpes zoster.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Vaccine component
- ATC class: J07BB03
- Indications: 33 conditions
- Clinical trials: 16
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2109042 |
| Name | Influenza Virus Vaccine |
| Type | Vaccine component |
| Max phase | 3 |
| ATC | J07BB03 |
Also known as: Influenza virus vaccine, Influenza, live attenuated, INFLUENZA VIRUS VACCINE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
33 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| relapsing-remitting multiple sclerosis | 3 | MONDO:0005314 | EFO:0003929 |
| herpes zoster | 3 | MONDO:0005609 | EFO:0006510 |
| avian influenza | 3 | MONDO:0018695 | EFO:0005222 |
| acute coronary syndrome | 3 | MONDO:0005542 | EFO:0005672 |
| swine influenza | 3 | MONDO:0005460 | EFO:0005226 |
| influenza | 3 | MONDO:0005812 | EFO:0007328 |
| pneumococcal infection | 3 | MONDO:0005114 | EFO:0000772 |
| severe acute respiratory syndrome | 3 | MONDO:0005091 | MONDO:0100096 |
| respiratory syncytial virus infectious disease | 3 | MONDO:0001577 | EFO:1001413 |
| asthma | 3 | MONDO:0004979 | MONDO:0004979 |
| multiple sclerosis | 3 | MONDO:0005301 | MONDO:0005301 |
| escherichia coli infection | 3 | MONDO:0020920 | EFO:1001318 |
| B-cell chronic lymphocytic leukemia | 2 | MONDO:0004948 | EFO:0000095 |
| HIV infectious disease | 2 | MONDO:0005109 | EFO:0000764 |
| hematologic disorder | 2 | MONDO:0005570 | HP:0001871 |
| astrocytoma (excluding glioblastoma) | 2 | MONDO:0019781 | EFO:0000272 |
| oligodendroglioma | 2 | MONDO:0016695 | EFO:0000632 |
| gonorrhea | 2 | MONDO:0004277 | DOID:7551 |
| exocrine pancreatic carcinoma | 2 | MONDO:0005192 | EFO:0002618 |
| paraganglioma | 2 | MONDO:0000448 | EFO:1000453 |
| colorectal neoplasm | 2 | MONDO:0005335 | MONDO:0005575 |
| acute lymphoblastic leukemia | 1 | MONDO:0004967 | EFO:0000220 |
| neoplasm | 1 | MONDO:0005070 | EFO:0000616 |
| head and neck squamous cell carcinoma | 1 | MONDO:0010150 | EFO:0000181 |
| central nervous system neoplasm | 1 | MONDO:0006130 | EFO:1000158 |
| head and neck cancer | 1 | MONDO:0005627 | EFO:0006859 |
| breast neoplasm | 1 | MONDO:0021100 | MONDO:0007254 |
| juvenile idiopathic arthritis | 0 | MONDO:0011429 | EFO:0002609 |
5 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 16.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 4 |
| PHASE3 | 4 |
| PHASE2 | 4 |
| PHASE1/PHASE2 | 2 |
| Not specified | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00389532 | PHASE4 | COMPLETED | Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation of the 2006-2007 Fluzone® Vaccine |
| NCT00390884 | PHASE4 | COMPLETED | Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation. |
| NCT00835926 | PHASE4 | COMPLETED | A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination |
| NCT01946438 | PHASE4 | COMPLETED | Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults |
| NCT00464672 | PHASE3 | COMPLETED | Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old |
| NCT00700193 | PHASE3 | COMPLETED | A Study of the Safety, Tolerability & Immunogenicity of CSL Limited’s Influenza Virus Vaccine In a Paediatric Population |
| NCT00885105 | PHASE3 | COMPLETED | Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age |
| NCT01551810 | PHASE3 | COMPLETED | The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated) |
| NCT00264576 | PHASE2 | COMPLETED | Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults |
| NCT00845429 | PHASE2 | COMPLETED | Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects |
| NCT00858468 | PHASE1/PHASE2 | COMPLETED | Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age |
| NCT00945438 | PHASE2 | COMPLETED | Study of the Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation (Intradermal Route) |
| NCT02649192 | PHASE2 | COMPLETED | Influenza Virus Vaccine Plus Vitamin A and D Supplements for Prevention of Respiratory Virus Infections in Children |
| NCT06382311 | PHASE1/PHASE2 | COMPLETED | A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults |
| NCT00001080 | Not specified | WITHDRAWN | Effect of Vaccination on Turnover of Lamivudine (3TC) Sensitive and Resistant Virus Populations in HIV-1-Infected Individuals |
| NCT02675608 | Not specified | COMPLETED | Vaccine Efficacy in Diabetic and Elderly Patients |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).